| Allergan |
| |
Targeting Glaucoma: New Approaches |
|
| Introduction
L. Levin |
| | Pharmacology
of Bimatoprost (Lumigan)
D. Gil |
|
| Clinical Update on Lumigan
J.
Cheetham |
| |
Model for Neuroprotection in Glaucoma
L. Levin |
| | Brimonidine
as a Neuroprotective Agent
D. Gil |
|
| Questions & Answers
Moderated
by: L. Levin |
|
Senju |
| |
The Current Therapeutic Strategy for Ocular Diseases
Chairpersons:
H. Yamashita, A. Okumura |
|
| Potential for therapeutic use of calpain inhibitor
SJA6017 against ocular diseases
C. Fukiage |
|
| Therapeutic potential of Rho-associated protein
kinase inhibitor (Y-39983) in glaucoma
H. Tokushige |
| | BRONUCK
- the most efficient NSAID: Interim safety and efficacy - post marketing analysis
in Japan
M. Wada |
|
B & L |
| |
New sustained drug delivery system in the management of posterior segment
diseases |
| Technology
Introduction
Z. Butuner |
|
| Fluocinolone acetonide intravitreal implant
to treat posterior uveitis
C. Pavesio |
|
| Fluocinolone acetonide intravitreal implant
to treat diabetic macular edema
R. Danis |
|
Santen |
| |
Levofloxacin - A new effective antibiotic for ocular use |
| | Levofloxacin
0.5% eye drops - use in ocular infections and for the antimicrobial prophylaxis
in ophthalmic surgery
T. O'Brien |
| | Penetration
of levofloxacin 0.5% and ofloxacin 0.3% in the anterior chamber in patients undergoing
cataract surgery
S. Kulus |
| | An
endophthalmitis model of monotherapy with levofloxacin
J. Alio |
| Pharmacia
|
| |
Latanoprost update - the new 'Gold Standard' for medical treatment of IOP
Moderator: W. Stewart |
| | Update
on the safety and Efficacy of Latanoprost
W. Stewart |
| | Update on Xalacom, the first prostaglandin
combination
N. Pfeiffer |
| |
Prostaglandins, what are the basic differences
R. Feldman |
| Novartis
|
| Photodynamic therapy
Chairperson:
J. Monés |
| | Current
Trials on Visudyne
J. Monés |
| | Angiographic
features after photodynamic therapy
S. Michels |
| | PDT
and myopia
U.Menchini |
| | PDT
and Angioid Streaks
U. Menchini |
|
Eli Lilly |
| |
PKC Beta Inhibitor: A Potential New Approach to Diabetic Retinopathy |
| | Introduction
A. Alanis |
| | Protein Kinase C: A mediator & therapeutic
target in diabetic complications
R. Donnelly |
| | The
development of PKC-Beta Inhibitor in pre-clinical and clinical studies
T.W. Gardner |
